| 书目名称 | Neocarzinostatin | | 副标题 | The Past, Present, a | | 编辑 | Hiroshi Maeda (Professor and Chairman),Kiyoto Edo | | 视频video | http://file.papertrans.cn/663/662535/662535.mp4 | | 图书封面 |  | | 描述 | The 20th century has witnessed the great benefits of the development of antibi otics, which became a reality after World War IL More than 50 years ago I witnessed the miraculous therapeutic power of penicillin, when I was a student at the Tohoku University Medical School‘s Department of Bacteriology in Sendai, Japan. The late Dr. Kondo was a graduate student in the department at that time and developed the first crude penicillin preparation in Japan which was applied with dramatic results in two patients. Although there was patient-family consent at that time, ethics committees, randomization. mutagenesis tests, distribution studies, purity-criteria, and phar macokinetics were not yet in existence. Today, regulatory procedures have com plicated the whole drug-approval process. For example, any new antibiotics that have been proven effective in laboratory studies against gram-negative bacteria, as might exist in deadly plague bacteria, must still undergo a long and enormously costly regulatory process before they can be introduced to benefit society, and before government insurance can be applied. | | 出版日期 | Book 1997 | | 关键词 | SMANCS; antitumor protein; cancer chemotherapy; endiyene; neocarzinostatin (NCS); antibiotics; cancer; chem | | 版次 | 1 | | doi | https://doi.org/10.1007/978-4-431-66914-2 | | isbn_softcover | 978-4-431-66916-6 | | isbn_ebook | 978-4-431-66914-2 | | copyright | Springer Japan 1997 |
The information of publication is updating
|
|
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-8-26 17:14
发表于 2025-3-21 16:16:27
